CAMBRIDGE, Ontario, Canada: Septodont, a global pharmaceutical and medical device company specializing in dental pain management, has announced that its Canada-based pharma division, Novocol Pharma, will receive funding of over C$32 million from the Canadian government. The investment is part of a countrywide initiative to advance vaccines and therapeutics for COVID-19 on a national level.
As stated in a press release, the government of Canada had made investments of approximately C$1 billion in industrial research, vaccine and pharmaceutical development, and biomanufacturing capacity by mid-March. In order to further strengthen the private sector in the fight against the global COVID-19 pandemic, it has now made new monies available via its Strategic Innovation Fund.
As announced by Septodont, the investment in Novocol will help support a C$72.6 million project to expand the company’s facilities in Ontario, and this will increase biomanufacturing capacity for fill-finish sterile injectables, including vaccines.
“By creating such capacity and capabilities, Novocol will contribute to strengthening Canada’s preparedness for future pandemics, as well as create skilled jobs and economic development in the country’s biopharmaceutical ecosystem. As a contract development and manufacturing organization, our investment will provide valuable services to support Canadian and foreign biopharmaceutical innovators, starting from clinical trial materials through to commercial scale manufacturing,” Septodont CEO Olivier Schiller commented.
According to Johns Hopkins University, Canada had reported almost one million cases of COVID-19 and about 23,000 related deaths by the beginning of April.
SINGAPORE: The International Dental Exhibition and Meeting (IDEM) 2022 has been postponed owing to the travel and safety restrictions currently in place in ...
MILAN, Italy: Italy has become the European country worst affected by the COVID-19 outbreak, its confirmed cases of infection currently reaching 74,386, ...
HELSINKI, Finland: Planmeca continues to invest heavily in modernising its in-house production in Helsinki. A newly inaugurated machining centre, modernised...
LEEDS, England: While antibiotics remain essential for treating infectious diseases, their global efficacy is declining owing to the rise of antimicrobial ...
WASHINGTON, U.S.: Drug prices in the U.S. are the highest in any developed country in the world, with a particular increase over the past decade. This trend...
GREIFSWALD, Germany: A study by researchers at University Medicine Greifswald compared the risk of SARS-CoV-2 transmission among dental teams with that of ...
BRNO, Czech Republic: A recent study carried out by scientists from Masaryk University in Brno has suggested that there may be a link between new‐onset ...
LONDON, England: The current state of public health dentistry in the UK is, without question, lamentable. Plagued by financial, personnel and regulatory ...
GENEVA, Switzerland: The SARS-CoV-2 outbreak is causing significant disruption to dental practice worldwide. Oral health professionals, dental associations ...
The coronavirus (COVID-19) pandemic is an unprecedented ongoing global health crisis, which has already led to loss of too many lives. Global businesses ...
Live webinar
Wed. 15 October 2025
7:00 pm EST (New York)
Dr. Julie Driscoll DMD, FAGD
Live webinar
Thu. 16 October 2025
9:00 am EST (New York)
Live webinar
Thu. 16 October 2025
6:00 pm EST (New York)
Live webinar
Thu. 16 October 2025
8:00 pm EST (New York)
Live webinar
Fri. 17 October 2025
7:00 am EST (New York)
Dr. David Trujillo, Mr. Giulio Bianchini
Live webinar
Fri. 17 October 2025
8:00 am EST (New York)
Dr. Lawrence Brecht, Dr. Robert Gottlander DDS
Live webinar
Fri. 17 October 2025
9:00 am EST (New York)
To post a reply please login or register